Nahid F Mivechi
Overview
Explore the profile of Nahid F Mivechi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McGrath M, Abolhassani A, Guy L, Elshazly A, Barrett J, Mivechi N, et al.
Front Endocrinol (Lausanne)
. 2024 Apr;
15:1298423.
PMID: 38567308
Estrogen receptor positive (ER) breast cancer is the most common breast cancer diagnosed annually in the US with endocrine-based therapy as standard-of-care for this breast cancer subtype. Endocrine therapy includes...
2.
Jin X, Moskophidis D, Mivechi N
Methods Mol Biol
. 2023 Aug;
2693:81-94.
PMID: 37540428
Mammalian heat shock factor HSF1 transcriptional activity is controlled by a multitude of phosphorylations that occur under physiological conditions or following exposure of cells to a variety of stresses. One...
3.
Xi C, Pang J, Barrett A, Horuzsko A, Ande S, Mivechi N, et al.
Mol Cancer Res
. 2023 Jun;
21(10):1079-1092.
PMID: 37364049
Implications: This study highlights that Nrf2 integrates metabolic and epigenetic regulatory networks to dictate tumor progression and that Nrf2 targeting is therapeutically exploitable in HCC treatment.
4.
Eroglu B, Jin X, Deane S, Ozturk B, Ross O, Moskophidis D, et al.
Cell Mol Life Sci
. 2022 Mar;
79(4):198.
PMID: 35313355
The dual specificity protein phosphatases (Dusps) control dephosphorylation of mitogen-activated protein kinases (MAPKs) as well as other substrates. Here, we report that Dusp26, which is highly expressed in neuroblastoma cells...
5.
Pang J, Gao J, Zhang L, Mivechi N, Ko L
Front Oral Health
. 2021 Sep;
2.
PMID: 34476412
Tumor angiogenesis is a hallmark of cancer. Therapeutic drug inhibitors targeting angiogenesis are clinically effective. We have previously identified GT198 (gene symbol also known as Hop2) as an oncoprotein that...
6.
Achyut B, Zhang H, Angara K, Mivechi N, Arbab A, Ko L
Cancer Lett
. 2020 Feb;
476:57-66.
PMID: 32061755
Targeting early lesion in breast cancer is more therapeutically effective. We have previously identified an oncoprotein GT198 (PSMC3IP) in human breast cancer. Here we investigated GT198 in MMTV-PyMT mouse mammary...
7.
Eroglu B, Pang J, Jin X, Xi C, Moskophidis D, Mivechi N
Mol Cancer Res
. 2019 Nov;
18(3):463-476.
PMID: 31744878
Deregulated oncogenic signaling linked to PI3K/AKT and mTORC1 pathway activation is a hallmark of human T-cell acute leukemia (T-ALL) pathogenesis and contributes to leukemic cell resistance and adverse prognosis. Notably,...
8.
Cho W, Jin X, Pang J, Wang Y, Mivechi N, Moskophidis D
Mol Cell Biol
. 2019 Feb;
39(9).
PMID: 30745413
Delineating the mechanisms that drive hepatic injury and hepatocellular carcinoma (HCC) progression is critical for development of novel treatments for recurrent and advanced HCC but also for the development of...
9.
Jin X, Qiao A, Moskophidis D, Mivechi N
Mol Cell Biol
. 2018 Jun;
38(18).
PMID: 29941492
Activation of the adaptive response to cellular stress orchestrated by heat shock factor 1 (HSF1), which is an evolutionarily conserved transcriptional regulator of chaperone response and cellular bioenergetics in diverse...
10.
Jin X, Eroglu B, Moskophidis D, Mivechi N
Methods Mol Biol
. 2017 Nov;
1709:1-22.
PMID: 29177647
Heat shock transcription factors (Hsfs) regulate transcription of heat shock proteins as well as other genes whose promoters contain heat shock elements (HSEs). There are at least five Hsfs in...